DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/mlzzbq/the_new_trends_of) has announced the addition of the "The New Trends of Global Preclinical Development Outsourcing Market" report to their offering.
The global preclinical development and toxicology research outsourcing market will likely experience a CAGR of 7% between 2015 and 2020 and will reach around $6.8 B by 2020. By then the outsourcing penetration in preclinical development is expected to reach about 45%.
The New Trends of Global Preclinical Development Outsourcing Market, provides unique insights into the current development states and the future growth potentials of the global preclinical development outsourcing market. The report is designed to reveal the latest development trends in this market, including the detailed insights of the new R&D strategies of major pharma companies and R&D-focused biotech companies on preclinical development and toxicology research and their outsourcing demands. It also includes the analyses on new technologies and service models that are currently evolving. Most importantly, the report contains the in-depth analyses of all positive and negative factors that might control the future growth directions of the global preclinical development outsourcing market.
The report provides readers a complete picture of the current state of the global preclinical development and toxicology research outsourcing market and a clear insight of its future growth potential. It is a must-read book to all pharmaceutical and biotechnology companies that seek preclinical development outsourcing opportunities, the preclinical development and toxicology research-focused service providers that need to conceive their future development directions, and venture capital investors that are looking for investment opportunities in the global pharmaceutical outsourcing industry.
Key Findings of the Report:
- Today all drug companies large or small have realized that they are in a dilemma situation: The drug R&D cost has been climbing up exponentially while the output of their R&D effort measured by the number of new drugs approved each year has remained low.
- To realize these goals, a new model of virtually integrated pharmaceutical operation through networked partnerships has evolved in the industry.
- As part of the lengthy process of drug discovery and development, preclinical development, including extensive in vitro pharmacological property profiling and toxicology studies, plays increasingly important roles in reducing the attrition rate for clinical development and overall drug R&D cost.
- Primarily driven by drug companies' these strong desires, preclinical development has undergone dramatic changes in the recent years. New technologies and R&D methodologies, drug companies' strategies and focuses, and even new outsourcing models have been constantly evolving.
- Today drug discovery CROs without in-depth preclinical development service capability gradually fall behind.
- Although the strong growth of the worldwide demand for preclinical development and toxicology research services just turns back very recently, whether this trend will still continue in the foreseeable future is determined by a number of factors and still remains to see.
- To further improve the productivity in their R&D, all drug companies are expected to still make changes in their R&D strategies, including their outsourcing strategies, in the near future in particular in discovery research and preclinical development.
- On the positive side, the whole industry is currently focusing on proof-of-concept study, development and incorporation of biomarkers into early stage R&D, and development of biologic drugs including biosimilars.
- On the negative side, major pharma companies' current main focus has still been on late stage development.
- Overall, although the outsourcing service demand for preclinical development may still experience fluctuations, all above situations combined together determine that this market may still experience positive growth in the near future.
- Within the global preclinical development outsourcing market, China is expected to play more important roles.
For more information visit http://www.researchandmarkets.com/research/mlzzbq/the_new_trends_of
